Armistice Capital’s Dare Bioscience DARE Stock Holding History

Armistice Capital’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-539,167	Closed	-$2.99M	–	320
2023 Q3	$2.99M	Buy	+539,167	New	+$4.44M	0.05%	124

Other funds holding DARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FFS

Founders Financial Securities Towson, Maryland $1.77B AUM 17.63% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Visionary Horizons Knoxville, Tennessee $239M AUM 22.35% 1-Year Est. Return

Armistice Capital's DARE Position: Q4 2023 in Review

Armistice Capital sold out of Dare Bioscience (DARE) in Q4 2023, closing a stake of 539,167 shares — an estimated $2.99M sold.

Armistice Capital first reported a position in DARE in Q3 2023 and held it in 1 quarter. The position peaked at $2.99M in Q3 2023. 35 funds tracked by Wall St. Rank hold DARE as of Q4 2023.

Armistice Capital reported no remaining Dare Bioscience position as of Q4 2023 after selling out during the quarter.
Armistice Capital sold 539,167 Dare Bioscience shares in Q4 2023, an estimated $2.99M.
Armistice Capital first reported a position in Dare Bioscience in Q3 2023 and held it in 1 quarter.
Armistice Capital's Dare Bioscience position peaked at $2.99M in Q3 2023.
35 funds tracked by Wall St. Rank held Dare Bioscience as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.